HSBC's Global Capabilities for the Biopharmaceutical Industry

blonca9
Mar 20, 2024
1 min read

Reece Kresser, Managing Director, U.S. Biopharmaceutical Investment Banking for HSBC, describes the increasingly global nature of our industry and how HSBC can match companies with global investors.

To learn more about how HSBC can partner to help your company go global, please reach out to Reece: Reece.Kresser@us.hsbc.com.

#Sponsored

Recent Posts

See All

Biotech investor Christoph Broja of EQT Life Sciences discusses biotech in Europe and highlights portfolio companies Tubulis, Agomab Therapeutics, and PanTera

With a phase 3 trial for its PRAME cell therapy underway and a data update coming up at ASCO, Immatics is pushing to be a leader in TCR based cell therapies and T-cell engagers

Mosaic Therapeutics, which uses advanced computational methods and next-generation cancer models to design novel combination therapies, licensed an ERK1/2 and MDM2 inhibitor from Astex Pharmaceuticals

HSBC's Global Capabilities for the Biopharmaceutical Industry

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight